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1. INTRODUCTION {#joa312364-sec-0005}
===============

Atrial fibrillation (AF) is the most common sustained cardiac arrhythmia among elderly individuals,[^1^](#joa312364-bib-0001){ref-type="ref"}, [^2^](#joa312364-bib-0002){ref-type="ref"}, [^3^](#joa312364-bib-0003){ref-type="ref"} and it has enormous socioeconomic implications given the risk of mortality and morbidity resulting from stroke, congestive heart failure, dementia, and impaired quality of life.[^1^](#joa312364-bib-0001){ref-type="ref"}, [^2^](#joa312364-bib-0002){ref-type="ref"}, [^3^](#joa312364-bib-0003){ref-type="ref"}, [^4^](#joa312364-bib-0004){ref-type="ref"}, [^5^](#joa312364-bib-0005){ref-type="ref"} Frailty is also associated with more adverse clinical outcomes in elderly individuals admitted to the hospital. AF may be a marker of frailty in elderly individuals and may be related to a loss of independence in performing activities of daily living.[^6^](#joa312364-bib-0006){ref-type="ref"} AF could worsen the state of frailty, and patients with AF could have 4‐fold increased odds of being classified as frail, compared with patients without AF.[^7^](#joa312364-bib-0007){ref-type="ref"}

Recent trials involving AF[^8^](#joa312364-bib-0008){ref-type="ref"}, [^9^](#joa312364-bib-0009){ref-type="ref"} revealed a high (4.6% per year) rate of all‐cause death in patients with AF, with only one out of 10 deaths related to stroke and approximately five or six out of 10 deaths related to cardiovascular causes. Therefore, a more integrated and holistic approach beyond anticoagulation therapy for patients with AF has been advocated in guidelines to reduce mortality and adverse outcomes in AF.[^10^](#joa312364-bib-0010){ref-type="ref"}, [^11^](#joa312364-bib-0011){ref-type="ref"}, [^12^](#joa312364-bib-0012){ref-type="ref"} One way is to streamline management approaches that would be applicable across the entire AF patient pathway, starting with primary care and linking with secondary care (even for cardiologists and noncardiologists), and be understandable for patients with AF. The ABC (atrial fibrillation better care) pathway has been proposed as a simple, integrated approach.[^13^](#joa312364-bib-0013){ref-type="ref"} This pathway streamlines the care pathway as follows: "A" Avoid stroke with Anticoagulation; "B" Better symptom management (ie, patient‐centered, symptom‐directed decisions on rate vs rhythm control); and "C" Cardiovascular and comorbidity management, including lifestyle factors.[^13^](#joa312364-bib-0013){ref-type="ref"}

Application of the simple ABC pathway was associated with a lower risk of adverse outcomes in patients with AF in a post hoc analysis of a clinical trial cohort as well as other AF cohorts.[^14^](#joa312364-bib-0014){ref-type="ref"}, [^15^](#joa312364-bib-0015){ref-type="ref"}, [^16^](#joa312364-bib-0016){ref-type="ref"} However, the population‐based benefit on clinical outcomes owing to a compliance with the ABC pathway has not been previously evaluated in patients with AF at a high frailty risk. Give the close association between AF and frailty, this study aimed to evaluate whether compliance with the ABC pathway would improve population‐based clinical outcomes in patients with AF belonging to different frailty risk categories, using a nationwide AF cohort.

2. METHODS {#joa312364-sec-0006}
==========

2.1. Data source {#joa312364-sec-0007}
----------------

We performed a retrospective analysis of data from the national health claims database (NHIS‐2016‐4‐026) established by the National Health Insurance Service (NHIS) of Korea.[^1^](#joa312364-bib-0001){ref-type="ref"}, [^2^](#joa312364-bib-0002){ref-type="ref"}, [^3^](#joa312364-bib-0003){ref-type="ref"} The NHIS is a single insurer managed by the Korean government, and the majority (97.1%) of the Korean population are mandatory subscribers, with the remaining 3% of the population being medical aid subjects. Since 2006, information regarding Medical Aid beneficiaries has been incorporated into a single NHIS database. Therefore, the data extracted from the NHIS claims database are based on the entire Korean population. The NHIS claims database includes diagnoses, procedures, biochemical test results, prescription records, and demographic information. The database is open to researchers whose study protocols are approved by official review committees. This study was approved by the Institutional Review Board of Yonsei University Health System (4‐2016‐0179).

2.2. Study cohort {#joa312364-sec-0008}
-----------------

From the Korean NHIS database, a total of 955 111 patients with prevalent AF who were aged 18 years or older were identified from 1 January 2005 to 31 December 2015. Patients with valvular AF, such as those with any mechanical or bioprosthetic heart valves, mitral valve repair, or rheumatic mitral stenosis (n = 59 189); those without baseline health check‐up data up to 1 year before enrolment (n = 571 585); and those who had ischemic stroke (n = 61 350) were excluded. Finally, a total of 262,987 patients with nonvalvular AF were enrolled in the study to evaluate the impact of the ABC pathway on the long‐term clinical outcomes of these patients (Figure [1](#joa312364-fig-0001){ref-type="fig"}).

![Flowchart of study population enrolment and analyses. AF, atrial fibrillation; OAC, oral anticoagulant; NHIS, National Health Insurance Service](JOA3-36-668-g001){#joa312364-fig-0001}

For each patient, the Hospital Frailty Risk Score was calculated retrospectively using all available ICD‐10 diagnostic codes that were documented for the particular admission, as recommended by Gilbert et al.[^17^](#joa312364-bib-0017){ref-type="ref"} The score is an aggregate of 109 ICD‐10 diagnostic codes found to be associated with frailty‐based risk (Supplementary Table [S1](#joa312364-sup-0001){ref-type="supplementary-material"}). Each diagnostic code was assigned a specific value proportional to how strongly it predicted frailty. According to the aggregate score, patients were divided into three frailty‐based risk categories: low risk (\<5 points, n = 221 542), intermediate risk (5‐15 points, n = 37 341), and high risk (\>15 points, n = 4104).[^17^](#joa312364-bib-0017){ref-type="ref"}

2.3. Definition of the ABC pathway‐compliant group {#joa312364-sec-0009}
--------------------------------------------------

The integrated care group (ABC group) was defined according to the criteria summarized in Supplementary Figure [S1](#joa312364-sup-0001){ref-type="supplementary-material"}. "A" was defined as the use of oral anticoagulants, in accordance with guidelines, with high adherence (prescription covering ≥80% of days); "B" was defined in relation to visits requiring medical contact with outpatient clinics (\<5 visits per year during the follow‐up period); "C" was defined as optimal management of the main cardiovascular comorbidities (hypertension, heart failure, myocardial infarction, peripheral artery disease, stroke/transient ischemic attack \[TIA\], diabetes mellitus, and obesity). Optimal management of hypertension was defined as baseline blood pressure values \<140/90 mmHg. For obesity, body mass index less than 30 kg/m^2^ was considered optimal management. For other comorbidities, appropriate use of cardiovascular prevention medications according to current guidelines was considered optimal management. Patients who fulfilled all criteria were defined as the "ABC" group, and those who did not fulfill all criteria were defined as the "non‐ABC" group.

2.4. Comorbidities and endpoints {#joa312364-sec-0010}
--------------------------------

AF was identified using International Classification of Disease, Tenth Revision (ICD‐10) codes: I48. To ensure accuracy, the diagnosis was established based on more than one or two outpatient records of ICD‐10 codes in the database. The diagnosis of AF has previously been validated in the NHIS database, with a positive predictive value of 94.1%.[^1^](#joa312364-bib-0001){ref-type="ref"}, [^4^](#joa312364-bib-0004){ref-type="ref"}, [^18^](#joa312364-bib-0018){ref-type="ref"}, [^19^](#joa312364-bib-0019){ref-type="ref"} Comorbidities were identified from ICD‐10 codes and prescription, as in previous studies (Supplementary Table [S2](#joa312364-sup-0001){ref-type="supplementary-material"}).[^18^](#joa312364-bib-0018){ref-type="ref"}

The primary clinical outcomes of this study were all‐cause death, ischemic stroke, heart failure admission, acute myocardial infarction, major bleeding, and a composite outcome of these five outcomes. Any diagnosis of ischemic stroke in the emergency room or inpatient clinic with concomitant brain imaging studies, including computed tomography or magnetic resonance imaging, was defined as incident ischemic stroke. The accuracy of the diagnosis of ischemic stroke in the NHIS claims data has been previously validated.[^4^](#joa312364-bib-0004){ref-type="ref"} The other definitions of clinical outcomes are presented in Supplementary Table [S2](#joa312364-sup-0001){ref-type="supplementary-material"}. Patients were followed from the index date until the study outcomes occurred or up to the end of follow‐up, whichever occurred first.

2.5. Statistical analysis {#joa312364-sec-0011}
-------------------------

Categorical data are reported as proportions, while continuous data are reported as medians with interquartile ranges (IQRs). The categorical variables were compared using Fisher\'s exact test or Pearson chi‐square test, and continuous variables were compared using Student\'s *t* test. The main analyses compared the clinical outcomes between the ABC (ie, integrated care) and non‐ABC groups. Incidence rates were defined as events per 100 person‐years at risk but expressed as annualized percentage rates for comprehensiveness. The relationships between the total number of ABC criteria fulfilled and the clinical outcomes were also investigated.

The cumulative incidences of adverse outcomes were presented using Kaplan--Meier curves and compared across the groups using the log‐rank test. Using Cox proportional hazard regression model, the hazard ratios (HRs) for adverse outcomes according to the use of integrated care (ABC) were analyzed. Clinical variables including age, gender, heart failure, hypertension, diabetes mellitus, previous myocardial infarction, peripheral artery disease, economic status, CHA~2~DS~2~‐VASc, and HAS‐BLED score were adjusted for HR. *P*‐values \< 05 were considered significant. Statistical analyses were conducted using SAS version 9.3 (SAS Institute) and R version 3.3.2 (The R Foundation, [www.R‐project.org](http://www.R-project.org)).

3. RESULTS {#joa312364-sec-0012}
==========

3.1. Baseline characteristics {#joa312364-sec-0013}
-----------------------------

Comparisons between the ABC and non‐ABC groups are presented in Supplementary Table [S3](#joa312364-sup-0001){ref-type="supplementary-material"}. Compared with the non‐ABC group, patients in the ABC group were less likely to be female (39.4% vs 38.6%, *P* = .001) and had a lower mean age (65.0 \[IQR 56.0, 72.0\] vs 50.0 \[IQR 41.0, 58.0\], *P* \< .001). Compared with patients in the non‐ABC group, those in the ABC group had a lower prevalence of comorbidities, such as hypertension, heart failure, diabetes mellitus, stroke/TIA, hemorrhage stroke, vascular disease, chronic kidney disease, and dyslipidemia. In addition, patients in the ABC group had a lower mean CHA~2~DS~2~‐VASc score than that of patients in the non‐ABC group.

The baseline characteristics between patients with AF with different hospital frailty risk categories who were compliant and noncompliant with the ABC pathway are compared in Table [1](#joa312364-tbl-0001){ref-type="table"}. Multivariable analysis showed that in patients with high frailty risk, factors including age ≥65 years and female gender were independently associated with a likelihood of being compliant with the ABC pathway. In contrast, high CHA~2~DS~2~‐VASc score, hypertension, liver disease, or history of intracranial bleeding were related to noncompliance with the ABC pathway. In patients with intermediate and low frailty risk, heart failure, and vascular disease were also related to compliance with the ABC pathway (Table [2](#joa312364-tbl-0002){ref-type="table"}).

###### 

Comparison of baseline characteristics between patients with atrial fibrillation and different hospital frailty risks who were compliant with and not compliant with the ABC pathway

  Characteristics                  Low frailty risk   Intermediate frailty risk   High frailty risk                                                                        
  -------------------------------- ------------------ --------------------------- ------------------- -------------- ---------------- -------- ------------- ------------- --------
  Female                           38.1%              38.3%                       .522                45.2%          41.3%            \<.001   48.5%         42.5%         .088
  Age, y                           65 (50, 71)        50 (41, 57)                 \<.001              69 (60, 75)    53 (44, 60)      \<.001   73 (63, 79)   58 (49, 64)   \<.001
  Age ≥ 65                         50.2%              5.9%                        \<.001              65.1%          12.5%            \<.001   72.8%         23.6%         \<.001
  Age ≥ 75                         14.5%              1.6%                        \<.001              28.0%          4.4%             \<.001   41.6%         10.3%         \<.001
  Economic status                  12 (5, 17)         13 (6, 17)                  \<.001              13 (5, 17)     12 (6,16)        \<.001   12 (5,17)     9 (3,15)      \<.001
  CHA~2~DS~2~‐VASc score           2 (1, 3)           0 (0, 1)                    \<.001              3 (2, 4)       1 (0, 1)         \<.001   4 (2, 5)      1 (0, 2)      \<.001
  mHAS‐BLED score†                 2 (1, 3)           0 (0, 1)                    \<.001              2 (1, 3)       0 (0, 1)         \<.001   3 (2, 3)      1 (0, 1)      \<.001
  Hospital Frailty Risk Score      0 (0, 1.8)         0 (0, 1.6)                  \<.001              7.4 (6, 9.7)   6.9 (5.7, 8.9)   \<.001   18 (16, 22)   18 (16, 20)   \<.001
  Charlson comorbidity index       2 (1, 4)           1 (0, 2)                    \<.001              4 (2, 6)       2 (1, 3)         \<.001   6 (4, 9)      3 (2, 6)      \<.001
  Hypertension                     64.2%              6.5%                        \<.001              70.9%          11.2%            \<.001   78.4%         20.2%         \<.001
  Heart failure                    22.6%              1.6%                        \<.001              29.4%          2.5%             \<.001   38.3%         5.6%          \<.001
  Diabetes mellitus                17.9%              2.1%                        \<.001              29.8%          4.7%             \<.001   42.8%         10.3%         \<.001
  Previous ischemic stroke/ TIA    0.0%               0.0%                        ---                 0.0%           0.0%             ---      0.0%          0.0%          ---
  Previous MI                      6.2%               0.4%                        \<.001              11.4%          0.9%             \<.001   16.2%         1.7%          \<.001
  PAOD                             8.5%               0.7%                        \<.001              12.8%          1.6%             \<.001   17.1%         1.3%          \<.001
  Vascular disease                 13.8%              1.0%                        \<.001              21.9%          2.3%             \<.001   29.3%         2.6%          \<.001
  Hypertrophic cardiomyopathy      1.2%               0.6%                        \<.001              1.0%           0.5%             \<.001   0.7%          0.9%          \<.001
  Chronic kidney disease           2.3%               0.7%                        \<.001              7.7%           1.8%             \<.001   15.6%         5.2%          \<.001
  Liver disease                    36.1%              28.0%                       \<.001              48.9%          38.8%            \<.001   60.2%         50.6%         .005
  Malignant neoplasm               17.4%              14.0%                       \<.001              31.8%          22.5%            \<.001   41.5%         33.0%         .014
  Hyperthyroidism                  8.2%               7.3%                        \<.001              10.6%          8.4%             \<.001   12.8%         7.3%          .019
  Hypothyroidism                   6.8%               5.5%                        \<.001              10.1%          6.9%             \<.001   13.3%         12.0%         .643
  Venous thromboembolism           2.4%               1.8%                        \<.001              5.9%           4.0%             \<.001   11.4%         9.4%          .413
  COPD                             11.1%              3.6%                        \<.001              22.1%          7.1%             \<.001   31.5%         15.5%         \<.001
  Previous intracranial bleeding   0.4%               0.2%                        \<.001              2.6%           1.8%             .002     9.3%          2.6%          .001
  History of any bleeding          3.9%               2.5%                        \<.001              20.0%          13.7%            \<.001   40.3%         27.5%         \<.001
  Coagulation/ platelet defect     2.2%               1.5%                        \<.001              8.1%           5.4%             \<.001   16.4%         14.2%         .424
  Osteoporosis                     22.8%              10.1%                       \<.001              41.5%          19.1%            \<.001   55.7%         34.8%         \<.001
  Medications                                                                                                                                                              
  OAC, baseline                    4.0%               3.3%                        \<.001              4.7%           6.1%             \<.001   6.1%          18.1%         \<.001
  OAC, follow‐up                   30.9%              22.1%                       \<.001              26.8%          35.5%            \<.001   21.1%         58.5%         \<.001
  Antiplatelet, baseline           53.1%              14.2%                       \<.001              58.5%          22.9%            \<.001   65.1%         38.3%         \<.001
  Antiplatelet, follow‐up          68.3%              31.6%                       \<.001              58.1%          25.7%            \<.001   48.3%         31.8%         \<.001
  Statin                           25.2%              7.2%                        \<.001              34.0%          16.4%            \<.001   41.6%         33.1%         \<.001
  Beta blocker                     34.2%              7.2%                        \<.001              39.9%          13.0%            \<.001   47.3%         25.7%         \<.001
  ACE inhibitor/ARB                38.4%              5.1%                        \<.001              47.9%          12.6%            \<.001   58.3%         28.6%         \<.001
  Diuretics                        38.2%              5.2%                        \<.001              49.0%          13.3%            \<.001   59.1%         30.7%         \<.001
  Digoxin                          8.5%               1.3%                        \<.001              6.9%           1.2%             \<.001   7.3%          2.1%          \<.001

Values are presented as median (Q1, Q3, quartiles \[25th and 75th percentiles\]) or %. †Modified HAS‐BLED = hypertension, 1 point: \>65 years old, 1 point: stroke history, 1 point: bleeding history or predisposition, 1 point: liable international normalized ratio, not assessed: ethanol or drug abuse, 1 point: drug predisposing to bleeding, 1 point.

Abbreviations: ACE, angiotensin converting enzyme; ARB, angiotensin II receptor blocker; COPD, chronic obstructive pulmonary disease; MI, myocardial infarction; OAC, oral anticoagulant; PAOD, peripheral artery occlusive disease; TIA, transient ischemic attack.

John Wiley & Sons, Ltd

###### 

Factors associated with compliance to the ABC pathway in different frailty categories

                                Low frailty risk    Intermediate frailty risk   High frailty risk                               
  ----------------------------- ------------------- --------------------------- ------------------- -------- ------------------ --------
  Age ≥ 65 y                    1.07 (1.05‐1.09)    \<.001                      ---                 ---      1.06 (1.04‐1.08)   \<.001
  Age ≥ 75 y                    1.21 (1.19‐1.23)    \<.001                      1.12 (1.11‐1.13)    \<.001   ---                ---
  Female                        1.17 (1.15 ‐1.19)   \<.001                      1.09 (1.08‐1.10)    \<.001   1.05 (1.04‐1.07)   \<.001
  Economic status               1.00 (1.00‐1.00)    \<.001                      1.00 (1.00‐1.00)    \<.001   ---                ---
  CHA~2~DS~2~‐VASc score        0.93 (0.91‐0.95)    \<.001                      0.97 (0.96‐0.97)    \<.001   0.98 (0.97‐0.99)   \<.001
  HAS‐BLED score                ---                 ---                         1.02 (1.01‐1.02)    \<.001   ---                ---
  Hospital Frailty Risk Score   1.00 (1.00‐1.00)    \<.001                      ---                 ---      ---                ---
  Charlson comorbidity Index    1.00 (1.00‐1.00)    .005                        ---                 ---      ---                ---
  Heart failure                 1.05 (1.03‐1.07)    \<.001                      1.02 (1.01‐1.03)    \<.001   ---                ---
  Hypertension                  0.85 (0.84‐0.87)    \<.001                      0.88 (0.87‐0.89)    \<.001   0.94 (0.92‐0.96)   \<.001
  Diabetes                      1.03 (1.02‐1.05)    \<.001                      ---                 ---      ---                ---
  Previous MI                   1.03 (1.02‐1.05)    \<.001                      ---                 ---      ---                ---
  Vascular disease              1.05 (1.03‐1.07)    \<.001                      1.02 (1.01‐1.04)    \<.001   ‐                  ‐
  Liver disease                 0.99 (0.98‐0.99)    \<.001                      0.97 (0.96‐0.97)    \<.001   0.97 (0.96‐0.99)   .002
  Malignant neoplasm            1.02 (1.01‐1.02)    \<.001                      ---                 ---      ---                ---
  Hyperthyroidism               0.99 (0.98‐0.99)    \<.001                      0.99 (0.98‐1.00)    .017     ---                ---
  Venous thromboembolism        1.01 (1.00‐1.02)    .031                        ---                 ---      ---                ---
  Intracranial bleeding         0.97 (0.95‐0.99)    .006                        0.97 (0.95‐0.99)    \<.001   0.96 (0.94‐0.99)   .003
  History of bleeding           ---                 ---                         0.99 (0.98‐1.00)    .004     0.98 (0.97‐1.00)   .013
  COPD                          1.01 (1.00‐1.01)    .008                        ---                 ---      ---                ---
  Osteoporosis                  0.99 (0.99‐1.00)    \<.001                      ---                 ---      ---                ---
  OAC use                       1.10 (1.09‐1.11)    \<.001                      1.08 (1.06‐1.10)    \<.001   1.05 (1.02‐1.09)   .005
  NOAC use                      ---                 ---                         1.37 (1.01‐1.87)    .044     ---                ---
  Antiplatelet use              1.04 (1.03‐1.05)    \<.001                      1.03 (1.01‐1.04)    \<.001   ---                ---
  Statin use                    1.01 (1.00‐1.01)    .005                        ---                 ---      ---                ---
  ACE inhibitor/ARB use         1.02 (1.01‐1.02)    \<.001                      1.01 (1.00‐1.02)    .005     ---                ---
  Diuretics use                 1.02 (1.02‐1.03)    \<.001                      1.02 (1.01‐1.02)    \<.001   ---                ---
  Digoxin use                   1.01 (1.01‐1.02)    \<.001                      ---                 ---      ---                ---

Abbreviations: CI, confidence interval; HR, hazard ratio; NOAC nonvitamin K antagonist oral anticoagulant. Other abbreviations are same as in Table [1](#joa312364-tbl-0001){ref-type="table"}.

John Wiley & Sons, Ltd

3.2. Death and composite outcomes {#joa312364-sec-0014}
---------------------------------

Patients with all three types of frailty risk in the ABC group had significantly lower cumulative incidences of all‐cause death (Figure [2A](#joa312364-fig-0002){ref-type="fig"}). During the mean follow‐up period of 5.9 (IQR 3.2, 9.4) years, compared with the non‐ABC group, the ABC group had lower rates of all‐cause death in the overall cohort (0.9 vs 3.3 per 100 person‐years, *P* \< .001), and in the low (0.7 vs 2.6 per 100 person‐years, *P* \< .001), intermediate (2.8 vs 7.2 per 100 person‐years, *P* \< .001), and high frailty risk groups (6.5 vs 17.5 per 100 person‐years, *P* \< .001) (Figure [3](#joa312364-fig-0003){ref-type="fig"}). After adjusting for clinical variables, compared with the non‐ABC group, the ABC group had a significantly lower risk of all‐cause death in the overall cohort (adjusted HR 0.93; 95% CI 0.90‐0.97, *P* \< .001), and in the low (adjusted HR 0.95; 95% CI 0.91‐0.99, *P* = .031), intermediate (adjusted HR 0.89; 95% CI 0.82‐0.97, *P* = .008), and high frailty risk groups (adjusted HR 0.74; 95% CI 0.56‐0.97, *P* = .031) (Figure [3](#joa312364-fig-0003){ref-type="fig"}). There was a significant statistical interaction for the three frailty categories, with the greatest benefit observed in the high frailty group (*P* ~int~ \< 0.001) (Figure [3](#joa312364-fig-0003){ref-type="fig"}).

![Cumulative incidences of all‐cause death (A) and composite outcomes (B) according to the use of integrated care (ABC) in patients with low (left panels), intermediate (mid panels), and high frailty risk (right panels)](JOA3-36-668-g002){#joa312364-fig-0002}

![Events, event rates, risk of all‐cause death, and composite outcomes according to the use of integrated care (ABC) in patients with different frailty risks. CI, confidence interval; HR, hazard ratio; PYRs, person‐years](JOA3-36-668-g003){#joa312364-fig-0003}

The ABC group had significantly lower cumulative incidences of composite outcomes in all three frailty risk groups (Figure [2B](#joa312364-fig-0002){ref-type="fig"}). During follow‐up, the ABC group had lower rates of composite outcomes in the overall cohort (2.0 vs 6.0 per 100 person‐years, *P* \< .001; adjusted HR 0.89; 95% CI 0.87‐0.92, *P* \< .001), and in the low (1.8 vs 5.3 per 100 person‐years, *P* \< .001; adjusted HR 0.90; 95% CI 0.87‐0.93, *P* \< .001) and intermediate (4.0 vs 11.3 per 100 person‐years, *P* = .009; adjusted HR 0.89; 95% CI 0.82‐0.97, *P* = .009) frailty risk groups (Figure [3](#joa312364-fig-0003){ref-type="fig"}). With regard to the composite outcomes in the high frailty group, there was no significant difference between the ABC and non‐ABC groups (10.5 vs 26.0 per 100 person‐years, *P* = .101; HR 0.79; 95% CI 0.59‐1.05, *P* = .101), and there was no statistically significant interaction for the three frailty categories (p~int~ = 0.063) (Figure [3](#joa312364-fig-0003){ref-type="fig"}).

3.3. Other outcomes {#joa312364-sec-0015}
-------------------

The Kaplan--Meier cumulative incidence curves for other outcomes are presented in Figure [4](#joa312364-fig-0004){ref-type="fig"}. Among AF patients with low and intermediate frailty risk, lower cumulative incidences of ischemic stroke, heart failure admission, acute myocardial infarction, and major bleeding were observed in the ABC group compared with the non‐ABC group (all log‐rank *P* \< .001). Among AF patients with high frailty risk, the lower cumulative incidence of clinical outcomes was also observed in the ABC group than in the non‐ABC group, but statistical significance was on the border.

![Cumulative incidences of ischemic stroke (A), heart failure admission (B), acute myocardial infarction (C), and major bleeding (D) according to use of integrated care (ABC) in patients with low (left panels), intermediate (mid panels), and high frailty risk (right panels). MI, myocardial infarction](JOA3-36-668-g004){#joa312364-fig-0004}

The event rates and risks for other outcomes according to the ABC and non‐ABC groups are presented in Figure [5](#joa312364-fig-0005){ref-type="fig"}. Compared with the non‐ABC group, the ABC group had lower event rates and risk of ischemic stroke, heart failure admission, and acute myocardial infarction in overall, low and intermediate frailty risk groups (all *P* \< .05). But among AF patients with high frailty risk group, there was no significant difference in risks of ischemic stroke, heart failure admission, and acute myocardial infarction between ABC and non‐ABC groups. Compared with the non‐ABC group, the ABC group had lower event rates and risk of major bleeding among patients with intermediate and high frailty risk, with a statistically significant interaction (*P* \< .001). But among AF patients with overall and low frailty risk group, there was no significant difference in the risk of major bleeding between ABC and non‐ABC groups.

![Events, event rates, and risks of other adverse outcomes according to the use of integrated care (ABC) in patients with different frailty risks. CI, confidence interval; HR, hazard ratio; PYRs, person‐years](JOA3-36-668-g005){#joa312364-fig-0005}

4. DISCUSSION {#joa312364-sec-0016}
=============

In this largest nationwide analysis of patients with AF according to frailty risk, the event rates and risks of the all‐cause death, ischemic stroke, heart failure admission, acute myocardial infarction, major bleeding, and composite of these outcomes were significantly lower in the ABC group than in the non‐ABC group. In addition, among patients with high frailty risk, compared with patients in the non‐ABC group, those in the ABC group had lower rates of all‐cause death; however, the composite outcome was nonsignificantly lower in the ABC group. When the three frailty categories were compared, the greatest benefit on mortality was observed in the high frailty group; however, with regard to the composite outcome, there was no statistical interaction for the three frailty categories. Given the close association between AF and frailty and the high healthcare burden associated with AF, a streamlined holistic approach to the management of AF would improve outcomes in such patients.

4.1. Mortality and outcomes according to frailty risk {#joa312364-sec-0017}
-----------------------------------------------------

The use of an integrated care approach to AF management has been associated with reduced cardiovascular hospitalization and all‐cause mortality.[^20^](#joa312364-bib-0020){ref-type="ref"} Nevertheless, approaches for providing integrated care have varying complexity.[^11^](#joa312364-bib-0011){ref-type="ref"} There is a need to have a simple, practical, and easily operational method to streamline the decision‐making management approaches to allow uniform applicability across the entire AF patient pathway, linking primary care and secondary care (including cardiologist and noncardiologists), and to be understandable for patients with AF, facilitating their engagement.

The ABC pathway was proposed to streamline the interventions and decision‐making, and to optimize the patient management pathway, providing simple guidance for the main components of integrated care.[^13^](#joa312364-bib-0013){ref-type="ref"} Recent AF management guidelines have incorporated the ABC pathway.[^12^](#joa312364-bib-0012){ref-type="ref"}, [^21^](#joa312364-bib-0021){ref-type="ref"} Nevertheless, there are limited data on the value of the ABC pathway in high‐risk patient groups. In this study, we show that the ABC pathway was related to reduced mortality and composite outcomes in frail patients with AF. The strong impact of the ABC pathway on overall mortality substantiates and strengthens the concept that a holistic approach for integrated management is associated with a significant clinical benefit for patients with AF. Indeed, compliance to the ABC pathway was also associated with a lower risk of ischemic stroke, heart failure admission, and acute myocardial infarction, as well as major bleeding, in patients with AF. A greater benefit in terms of major bleeding was observed in patients with AF and high frailty risk.

Although the risk of thromboembolic events is high, the rate of adequate oral anticoagulation is lower in frail patients with AF compared to nonfrail patients.[^8^](#joa312364-bib-0008){ref-type="ref"}, [^9^](#joa312364-bib-0009){ref-type="ref"}, [^10^](#joa312364-bib-0010){ref-type="ref"} However, specific suggestions on oral anticoagulant (OAC) use have been based on advanced age and/or the presence of various comorbid disease states (eg, age \> 75, renal impairment, prior history of bleeding), but not on frailty.[^11^](#joa312364-bib-0011){ref-type="ref"}, [^12^](#joa312364-bib-0012){ref-type="ref"} It may be appropriate to use no anticoagulation to avoid bleeding events in severe frail patients with AF. A recent US cohort study has shown that rivaroxaban but not apixaban or dabigatran was associated with reduced stroke versus warfarin in frail patients with nonvalvular AF while no significant difference in bleeding versus warfarin.[^22^](#joa312364-bib-0022){ref-type="ref"} Therefore, "A" (Avoid stroke with Anticoagulation) as an integrated approach in patients with AF at a high frailty risk may not be always associated with good outcomes.

4.2. Study limitations {#joa312364-sec-0018}
----------------------

This retrospective population‐based observational study was performed using nationwide cohort data and should be interpreted in the context of the following limitations. First, the baseline diagnoses of AF, comorbidities, and clinical outcomes were dependent on the diagnostic codes registered by the physicians; therefore, these could be inaccurate, although the method for diagnosis has been validated in previous studies, and our internal validation found a high correlation with the actual diagnosis of AF.[^4^](#joa312364-bib-0004){ref-type="ref"} Second, patients included in the non‐ABC group appeared more complex from a clinical perspective, with multiple comorbidities; however, compared with the non‐ABC group, the ABC group had adjusted lower risk of all‐cause death and composite outcome in all subgroups regardless of age, gender, and comorbidities. Conversely, given the high prevalence of comorbidities in the non‐ABC group, we can speculate that full implementation of the ABC pathway may reduce the risk even further. Third, in this study based on claims data, we used adherence (≥80%) as a surrogate of OAC optimization use, but fully recognize the limitations of lack of time in therapeutic range (TTR) data in patients with vitamin K antagonist use, or the availability of label‐adherence prescribing. Fourth, this study defined the low frequency of medical contact as "B" (better symptom management). However, a symptom is just one of the factors to decide the frequency of medical contact. Our definition using the frequency of medical contact alone may not have sufficiently reflected "B" (better symptom management) of AF patients. Fifth, this study included some patients who have undergone catheter ablation for eliminating AF. In Castle AF trial, ablation for AF in patients with heart failure improved all‐caused death. Hence, ablation may influence the improvement of outcomes of patients. Finally, in this study, we enrolled only East Asian patients, and therefore, whether the results can be extrapolated to other ethnic populations remains uncertain. Despite these limitations, to the best of our knowledge, this study presents the largest nationwide population dataset available in the literature to investigate the relationship between frailty and cardiovascular outcomes in patients with AF.

5. CONCLUSIONS {#joa312364-sec-0019}
==============

Compliance with the simple ABC pathway is associated with improved outcomes in patients with AF who have a high frailty risk. Given the high healthcare burden associated with AF, such a streamlined holistic approach to the management of AF should be implemented to improve outcomes in such patients.
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